The Calpain Hypothesis of Neurodegeneration: Evidence for a Common Cytotoxic Pathway

Calpain's general function and pathogenic role in the CNS are reviewed. Collectively, the literature indicates that calpain proteolysis plays a common and important role in a variety of acute neurodegenerative conditions, including focal ischemia (stroke), global ischemia, traumatic brain injury, and spinal cord injury. This evidence indicates that 1) calpain is activated in an abnormally sustained fashion during cellular events commonly associated with neurodegeneration (e.g., excessive interstitial glutamate and cytosolic calcium); 2) many of calpain's preferred substrates are degraded as important components in these neurodegenerative conditions; 3) calpain activation occurs early in the pathogenic cascade of each, prior to onset of substantial cell death; and 4) calpain inhibitors can effectively reduce the severity of neuronal damage and loss of function normally associated with these acute neurodegenerative perturbations. Calpain proteolysis is also implicated in chronic neurodegenerative diseases, with the strength of current evidence varying among specific diseases. The evidence accumulated for a plausible role in Alzheimer's disease (AD) is currently the strongest. For example, empirical links have been established between abnormal calpain proteolysis and 1) the cellular formation of classic Alzheimer's pathology, such as β-amyloid plaques, neurofibrillary tangles, and Alz-50 immunoreactivity; 2) the brain regions with greatest concentrations of AD-related pathology; and 3) the degeneration of key brain pathways vulnerable in the early stages of the disease. Similar, though less extensive, evidence exists for a potential role of abnormal calpain proteolysis in Parkinson's disease. Finally, for several other chronic neurodegenerative conditions (e.g., Huntington's disease and amyotrophic lateral sclerosis), early evidence is emerging that calpain may also play some pathogenic role. Thus, these data support the possibility that uncontrolled calpain proteolysis may contribute to and/or accelerate the loss of neurons associated with a wide range of neurodegenerative conditions and may, therefore, represent an important, final common cytotoxic pathway for many diverse forms of neurodegeneration. NEUROSCIENTIST 3:314–327, 1997

[1]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[2]  K. Suzuki,et al.  Calpain: novel family members, activation, and physiologic function. , 1995, Biological chemistry Hoppe-Seyler.

[3]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[4]  H. Kawasaki,et al.  Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Masters,et al.  Proteolytic Processing of Alzheimer's Disease βA4 Amyloid Precursor Protein in Human Platelets (*) , 1995, The Journal of Biological Chemistry.

[6]  Z. Khachaturian Calcium Hypothesis of Alzheimer's Disease and Brain Aging a , 1994, Annals of the New York Academy of Sciences.

[7]  R. Siman,et al.  Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  B. Horecker,et al.  Effects of a monoclonal anti-calpain antibody on responses of stimulated human neutrophils. Evidence for a role for proteolytically modified protein kinase C. , 1988, The Journal of biological chemistry.

[9]  G. Clifton,et al.  A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat , 1997, Neuroscience.

[10]  H. Sorimachi,et al.  New era of calpain research , 1994, FEBS letters.

[11]  R. Nixon,et al.  Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease , 1997, Brain Research.

[12]  G. Lynch,et al.  Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[14]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[15]  M. Pontecorvo,et al.  Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholinergic deficiencies , 1985, Pharmacology Biochemistry and Behavior.

[16]  R. Nixon Calcium‐Activated Neutral Proteinases as Regulators of Cellular Function Implications for Alzheimer's Disease Pathogenesis a , 1989, Annals of the New York Academy of Sciences.

[17]  J. Card,et al.  Proteolytic processing of beta-amyloid precursor by calpain I , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[18]  J. Krieglstein,et al.  Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo , 1993, Brain Research.

[19]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[20]  R. Hayes,et al.  Calpain inhibitors reduce depolarization induced loss of tau protein in primary septo-hippocampal cultures , 1995, Neuroscience Letters.

[21]  R. Bartus Physostigmine and recent memory: effects in young and aged nonhuman primates. , 1979, Science.

[22]  P. Emson,et al.  Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease , 1991, Brain Research.

[23]  R. Bartus,et al.  Calpain as a novel target for treating acute neurodegenerative disorders. , 1995, Neurological research.

[24]  R. Hayes,et al.  Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. , 1994, Journal of neurotrauma.

[25]  E. Hogan,et al.  Changes in myelin and axonal proteins in CaCl2-induced myelopathy in rat spinal cord. , 1984, Central nervous system trauma : journal of the American Paralysis Association.

[26]  D. Choi,et al.  Glutamate neurotoxicity and diseases of the nervous system , 1988, Neuron.

[27]  E. Hogan,et al.  Calpain secreted by activated human lymphoid cells degrades myelin , 1995, Journal of neuroscience research.

[28]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[29]  K. Suzuki,et al.  Spatial resolution of fodrin proteolysis in postischemic brain. , 1993, The Journal of biological chemistry.

[30]  G. Clifton,et al.  Cytoskeletal Derangements of Cortical Neuronal Processes Three Hours after Traumatic Brain Injury in Rats: An Immunofluorescence Study , 1996, Journal of neuropathology and experimental neurology.

[31]  E. Masliah,et al.  Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? , 1990, Brain Research.

[32]  R. Hayes,et al.  Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. , 1992, Journal of neurotrauma.

[33]  E. Hogan,et al.  Calpain Expression in Lymphoid Cells , 1995, The Journal of Biological Chemistry.

[34]  E. Hogan,et al.  Role of calpain in spinal cord injury: increased mcalpain immunoreactivity in spinal cord after compression injury in the rat , 1995, Neurochemistry International.

[35]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Bozyczko‐Coyne,et al.  Prolonged Calpain‐mediated Spectrin Breakdown Occurs Regionally Following Experimental Brain Injury in the Rat , 1996, Journal of neuropathology and experimental neurology.

[37]  R. Bartus,et al.  Postischemic Administration of AK275, a Calpain Inhibitor, Provides Substantial Protection against Focal Ischemic Brain Damage , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[38]  R. Nixon,et al.  Calcium Influx into Human Neuroblastoma Cells Induces ALZ‐50 Immunoreactivity: Involvement of Calpain‐Mediated Hydrolysis of Protein Kinase C , 1996, Journal of neurochemistry.

[39]  G. Lynch,et al.  Inhibition of proteolysis protects hippocampal neurons from ischemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  T B Shea,et al.  Calcium‐Activated Neutral Proteinase (Calpain) System in Aging and Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.

[41]  M. Ginsberg Review : Neuroprotection in Brain Ischemia: An Update (Part II , 1995 .

[42]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  J. LaManna,et al.  Local Cerebral Glucose Utilization and Cytoskeletal Proteolysis as Indices of Evolving Focal Ischemic Injury in Core and Penumbra , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  G. Lynch,et al.  The biochemistry of memory: a new and specific hypothesis. , 1984, Science.

[45]  B. Siesjö,et al.  Calcium Fluxes, Calcium Antagonists, and Calcium-Related Pathology in Brain Ischemia, Hypoglycemia, and Spreading Depression: A Unifying Hypothesis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[46]  KEVIN S. Lee,et al.  Neuroprotection With a Calpain Inhibitor in a Model of Focal Cerebral Ischemia , 1994, Stroke.

[47]  E. Hirsch,et al.  Increased m-calpain expression in the mesencephalon of patients with parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? , 1996, Neuroscience.

[48]  J. Olney,et al.  Glutamate and the pathophysiology of hypoxic–ischemic brain damage , 1986, Annals of neurology.

[49]  G. Lynch,et al.  Time-Related Neuronal Changes following Middle Cerebral Artery Occlusion: Implications for Therapeutic Intervention and the Role of Calpain , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  K. Suzuki,et al.  Calcium activated neutral protease--structure-function relationship and functional implications. , 1990, Cell structure and function.

[51]  R. Bartus,et al.  Calpain Inhibitor AK295 Protects Neurons From Focal Brain Ischemia: Effects of Postocdusion Intra-arterial Administration , 1994, Stroke.

[52]  R. Nixon,et al.  Enhancement of Neurite Outgrowth Following Calpain Inhibition Is Mediated by Protein Kinase C , 1995, Journal of neurochemistry.

[53]  R. Bartus,et al.  The cholinergic hypothesis of geriatric memory dysfunction. , 1982, Science.

[54]  S. Kadoya,et al.  Morphometric assessment of drug effects in experimental spinal cord injury. , 1986, Journal of neurosurgery.

[55]  G. Lynch,et al.  Calmodulin stimulates the degradation of brain spectrin by calpain , 1987, Synapse.

[56]  S. Shimohama,et al.  Presence of calpain II immunoreactivity in senile plaques in Alzheimer's disease , 1991, Brain Research.

[57]  R. Bartus Drugs to Treat Age‐Related Neurodegenerative Problems The Final Frontier of Medical Science? , 1990, Journal of the American Geriatrics Society.

[58]  G. Lynch,et al.  Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus , 1989, Brain Research.

[59]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[60]  D. Paty,et al.  Urinary myelin basic protein—like material as a correlate of the progression of multiple sclerosis , 1995, Annals of neurology.

[61]  F. Schottler,et al.  Calcium-activated proteolysis in rat neocortex induced by transient focal ischemia , 1994, Brain Research.

[62]  T. Mcintosh Neurochemical sequelae of traumatic brain injury: therapeutic implications. , 1994, Cerebrovascular and brain metabolism reviews.

[63]  G. Lynch,et al.  Presence of brain spectrin in dendrites of mammalian brain: Technical factors involved in immunocytochemical detection , 1988, Synapse.

[64]  K. Matsushima,et al.  Calcium-dependent binding of phosphorylated human pre interleukin 1 alpha to phospholipids. , 1990, Journal of biochemistry.

[65]  R. Bartus,et al.  Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[66]  K. Wang,et al.  Calpain inhibition: an overview of its therapeutic potential. , 1994, Trends in pharmacological sciences.

[67]  G. Lynch,et al.  Temporal ordering of pathogenic events following transient global ischemia , 1998, Brain Research.

[68]  R. Nixon,et al.  Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[69]  H. Sorimachi,et al.  Calpain: new perspectives in molecular diversity and physiological‐pathological involvement , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  K. Blomgren,et al.  Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue , 1990, Neurobiology of Aging.

[71]  A. Young,et al.  Excitatory amino acids and Alzheimer's disease , 1989, Neurobiology of Aging.

[72]  R. Bartus,et al.  Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat , 1983, Pharmacology Biochemistry and Behavior.